New Zealand - English - Ministry for Primary Industries

zoetis new zealand limited - hendra virus (hev) soluble g (sg) protein - hendra virus (hev) soluble g (sg) protein 0 vaccine - vaccine

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - influenza virus haemagglutinin -

Canada - English - Health Canada

aventis pasteur limited - poliovirus vaccine live orl-trival human type-1; poliovirus vaccine live orl-trival human type-2; poliovirus vaccine live orl-trival human type-3 - suspension - 1000000unit; 100000unit; 300000unit - poliovirus vaccine live orl-trival human type-1 1000000unit; poliovirus vaccine live orl-trival human type-2 100000unit; poliovirus vaccine live orl-trival human type-3 300000unit - vaccines

Canada - English - Health Canada

wyeth ltd. - adenovirus vaccine live oral type-4 - tablet - nil - adenovirus vaccine live oral type-4 nil - vaccines

Canada - English - Health Canada

wyeth ltd. - adenovirus vaccine live oral type-7 - tablet - nil - adenovirus vaccine live oral type-7 nil - vaccines

Canada - English - Health Canada

aventis pasteur limited - poliovirus vaccine live orl-trival human type-1; poliovirus vaccine live orl-trival human type-2; poliovirus vaccine live orl-trival human type-3 - solution - 1000000unit; 100000unit; 150000unit - poliovirus vaccine live orl-trival human type-1 1000000unit; poliovirus vaccine live orl-trival human type-2 100000unit; poliovirus vaccine live orl-trival human type-3 150000unit - vaccines

United States - English - NLM (National Library of Medicine)

merck sharp & dohme llc - measles virus strain enders' attenuated edmonston live antigen (unii: mfz8i7277d) (measles virus strain enders' attenuated edmonston live antigen - unii:mfz8i7277d), mumps virus strain b level jeryl lynn live antigen (unii: 47qb6mx9ku) (mumps virus strain b level jeryl lynn live antigen - unii:47qb6mx9ku), rubella virus strain wistar ra 27/3 live antigen (unii: 52202h034z) (rubella virus strain wistar ra 27/3 live antigen - unii:52202h034z), varicella-zoster virus strain oka/merck live antigen (unii: gpv - measles virus strain enders' attenuated edmonston live antigen 1000 [tcid_50] in 0.5 ml - proquad is a vaccine indicated for active immunization for the prevention of measles, mumps, rubella, and varicella in children 12 months through 12 years of age. do not administer proquad to individuals with a history of hypersensitivity to any component of the vaccine (including gelatin) {1} or to a previous dose of m-m-r ii (measles, mumps, rubella, live), proquad or varivax (varicella virus vaccine live) vaccine, or any other measles, mumps, and rubella or varicella-containing vaccine. do not administer proquad to individuals with a history of anaphylaxis to neomycin [see description (11)] . do not administer proquad vaccine to individuals who are immunodeficient or immunosuppressed due to disease or medical therapy. measles inclusion body encephalitis {2} (mibe), pneumonitis {3} and death as a direct consequence of disseminated measles vaccine virus infection have been reported in immunocompromised individuals inadvertently vaccinated with measles-containing vaccine. in this population, disseminated mump

United States - English - NLM (National Library of Medicine)

merck sharp & dohme llc - human papillomavirus type 6 l1 capsid protein antigen (unii: 61746o90dy) (human papillomavirus type 6 l1 capsid protein antigen - unii:61746o90dy), human papillomavirus type 11 l1 capsid protein antigen (unii: z845vhq61p) (human papillomavirus type 11 l1 capsid protein antigen - unii:z845vhq61p), human papillomavirus type 16 l1 capsid protein antigen (unii: 6lte2dnx63) (human papillomavirus type 16 l1 capsid protein antigen - unii:6lte2dnx63), human papillomavirus type 18 l1 capsid protein antigen (unii: - human papillomavirus type 6 l1 capsid protein antigen 20 ug in 0.5 ml - gardasil® is a vaccine indicated in girls and women 9 through 26 years of age for the prevention of the following diseases caused by human papillomavirus (hpv) types included in the vaccine: - cervical, vulvar, vaginal, and anal cancer caused by hpv types 16 and 18 - genital warts (condyloma acuminata) caused by hpv types 6 and 11 and the following precancerous or dysplastic lesions caused by hpv types 6, 11, 16, and 18: - cervical intraepithelial neoplasia (cin) grade 2/3 and cervical adenocarcinoma in situ (ais) - cervical intraepithelial neoplasia (cin) grade 1 - vulvar intraepithelial neoplasia (vin) grade 2 and grade 3 - vaginal intraepithelial neoplasia (vain) grade 2 and grade 3 - anal intraepithelial neoplasia (ain) grades 1, 2, and 3 gardasil is indicated in boys and men 9 through 26 years of age for the prevention of the following diseases caused by hpv types included in the vaccine: - anal cancer caused by hpv types 16 and 18 - genital warts (condyloma acuminata) caused by hpv types 6 and

United States - English - NLM (National Library of Medicine)

merck sharp & dohme llc - measles virus strain enders' attenuated edmonston live antigen (unii: mfz8i7277d) (measles virus strain enders' attenuated edmonston live antigen - unii:mfz8i7277d), mumps virus strain b level jeryl lynn live antigen (unii: 47qb6mx9ku) (mumps virus strain b level jeryl lynn live antigen - unii:47qb6mx9ku), rubella virus strain wistar ra 27/3 live antigen (unii: 52202h034z) (rubella virus strain wistar ra 27/3 live antigen - unii:52202h034z) - measles virus strain enders' attenuated edmonston live antigen 1000 [tcid_50] in 0.5 ml - m-m-r ii is a vaccine indicated for active immunization for the prevention of measles, mumps, and rubella in individuals 12 months of age and older. do not administer m-m-r ii vaccine to individuals with a history of hypersensitivity to any component of the vaccine (including gelatin) {3} or who have experienced a hypersensitivity reaction following administration of a previous dose of m-m-r ii vaccine or any other measles, mumps and rubella-containing vaccine. do not administer m-m-r ii vaccine to individuals with a history of anaphylaxis to neomycin [see description (11)]. do not administer m-m-r ii vaccine to individuals who are immunodeficient or immunosuppressed due to disease or medical therapy. measles inclusion body encephalitis {4} (mibe), pneumonitis {5} and death as a direct consequence of disseminated measles vaccine virus infection have been reported in immunocompromised individuals inadvertently vaccinated with measles-containing vaccine. in this population, disseminated mumps and rubella vaccin

United States - English - NLM (National Library of Medicine)

sanofi pasteur inc. - influenza a virus a/brisbane/02/2018 ivr-190 (h1n1) antigen (formaldehyde inactivated) (unii: xw4jb03ti5) (influenza a virus a/brisbane/02/2018 ivr-190 (h1n1) hemagglutinin antigen (formaldehyde inactivated) - unii:92xe6ghc89), influenza a virus a/kansas/14/2017 x-327 (h3n2) antigen (formaldehyde inactivated) (unii: 3nzw5nd3d6) (influenza a virus a/kansas/14/2017 x-327 (h3n2) hemagglutinin antigen (formaldehyde inactivated) - unii:k329ycd1n9), influenza b virus b/maryland/15/2016 bx-69a antigen (formaldeh - influenza a virus a/michigan/45/2015 x-275 (h1n1) hemagglutinin antigen (formaldehyde inactivated) 60 ug in 0.5 ml - fluzone® high-dose is a vaccine indicated for active immunization for the prevention of influenza disease caused by influenza a subtype viruses and type b virus contained in the vaccine. fluzone high-dose is approved for use in persons 65 years of age and older. a severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine [see description (11) ], including egg protein, or to a previous dose of any influenza vaccine is a contraindication to administration of fluzone high-dose. fluzone high-dose is not approved for use in persons <65 years of age. there are limited human data and no animal data available to establish whether there is a vaccine-associated risk with use of fluzone high-dose in pregnancy. fluzone high-dose is not approved for use in persons <65 years of age. no human or animal data are available to assess the effects of fluzone high-dose on the breastfed infant or on milk production/excretion. safety and effectiveness of fluzone high-dose in persons <65 years of age have not bee